] is involved in both motor and sensory functions in hollow organs, especially in the gastrointestinal tract. However, the involvement of 5-HT in visceral sensation of the urinary bladder remains unknown. Because distention-induced ATP release from the urothelium plays an essential role in visceral sensation of the urinary bladder, we investigated the regulation of urothelial ATP release by the 5-HT signaling system. RT-PCR and immunohistochemical analyses of the urothelium revealed specific expression of 5-HT 1D and 5-HT 4 receptors. The addition of 5-HT did not affect urothelial ATP release without bladder distention, but it significantly reduced distention-induced ATP release by physiological pressure during urine storage (5 cmH 2O). The inhibitory effect of 5-HT on distentionelicited ATP release was blocked by preincubation with the 5-HT 1B/1D antagonist GR-127935 but not by the 5-HT4 antagonist SB-204070. mRNA encoding tryptophan hydroxylase 1 was detected in the urinary bladder by nested RT-PCR amplification, and L-tryptophan or the selective serotonin reuptake inhibitor citalopram also inhibited ATP release, indicating that 5-HT is endogenously synthesized and released in the urinary bladder. The addition of GR-127935 significantly enhanced the distention-elicited ATP release 40 min after distention, whereas SB-204070 reduced the amount of ATP release 20 min after distention. These data suggest that 5-HT 4 facilitates the distention-induced ATP release at an earlier stage, whereas 5-HT1D inhibits ATP release at a later stage. The net inhibitory effect of 5-HT indicates that the action of 5-HT on the urothelium is mediated predominantly by 5-HT1D.
SEROTONIN [5-hydroxytryptamine (5-HT)
] is a multifunctional signaling molecule in visceromotor and viscerosensory systems. The multiple functions of 5-HT are mediated by various receptor subtypes (5-HT 1 to 5-HT 7 ) (24, 41) . In the gastrointestinal system, 5-HT can induce bowel contraction or relaxation by activating intrinsic excitatory or inhibitory motor neurons. Stimulation of 5-HT 3 or 5-HT 4 receptors on enteric cholinergic neurons results in the contraction of smooth muscles (6, 17, 51, 55) . 5-HT also stimulates 5-HT 1A , 5-HT 1D , and 5-HT 4 receptors on inhibitory neurons to release nitric oxide, thereby relaxing smooth muscle (6, 17, 51, 55) . Smooth muscle also expresses 5-HT receptors, including 5-HT 2A (mediating contraction), 5-HT 4 , and 5-HT 7 subtypes (mediating relaxation) (6, 17, 51, 55) . Furthermore, 5-HT participates in mucosal sensory transduction in the gastrointestinal system. Enterochromaffin cells in the mucosa release 5-HT in response to intraluminal pressure (5) . Released 5-HT activates extrinsic vagal afferent nerves to transmit sensations of nausea or discomfort (51) . The mucosal projection of intrinsic primary afferent neurons is also stimulated by 5-HT, which initiates peristaltic and secretory reflexes (51) .
In addition to the gastrointestinal system, 5-HT regulates the contraction of smooth muscle in the urinary bladder. 5-HT 1A , 5-HT 2 , 5-HT 3 , and 5-HT 7 receptors on the detrusor control its contractions (11, 13, 28, 29, 39, 45, 47, 48) . 5-HT 1A , 5-HT 2A , 5-HT 2C , 5-HT 3 , 5-HT 4 , and 5-HT 7 receptors in the terminals of autonomic excitatory neurons in the urinary bladder modulate neurogenic contractions of the detrusor (7, 11, 14, 38, 46, 57) . The micturition reflex is also regulated by spinal/supraspinal 5-HT 1A , 5-HT 2A , and 5-HT 7 receptors (8 -10, 15, 25-27, 36, 37, 44, 56) . However, the function of peripheral 5-HT receptors on visceral sensation of the urinary bladder remains unclear.
Recent studies have revealed that the release of ATP from the epithelium of the urinary bladder (urothelium) contributes to visceral sensation (2) (3) (4) . Distention of the bladder wall during urine storage evokes the release of ATP from the urothelium (16, (32) (33) (34) (35) . Studies using purinergic receptor P2X 3 -deficient mice (12) have suggested that the released ATP transmits viscerosensory signals to the central nervous system via P2X 3 at afferent nerve terminals in close proximity to the urothelium. Therefore, in the present study, we investigated the regulation of urothelial ATP release by bladder 5-HT receptors to reveal the contribution of peripheral 5-HT receptors to bladder visceral sensation.
MATERIALS AND METHODS
Animals. Six-to ten-week-old C57BL/6 male mice were used in this study. The protocols for the experiments in the present study were approved by The Animal Research Committee of Akita University and followed the guidelines of the American Physiological Society for animal research.
RT-PCR. Urinary bladders and brains were dissected from five mice. The urothelium and urothelium-denuded bladders were dissected and separated as follows: opened bladders were incubated in dispase solution (2,000 U/ml dispase II, Sanko Junyaku, Tokyo, Japan) prepared in minimum essential medium (Gibco, Invitrogen, Carlsbad, CA) for 1 h at 37°C. The urothelium was gently scraped from the underlying tissues. Total RNA was isolated from the brain, urothelium, and urothelium-denuded bladder using ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol. RNA samples were treated with deoxyribonuclease I (Sigma, St. Louis, MO) at room temperature for 10 min to exclude artifacts due to genomic DNA contamination. Synthesis of first-strand cDNA and PCR were performed using the Transcriptor One-Step RT-PCR Kit (Roche, Mannheim, Germany). First-strand cDNA was synthesized using Oligo(dT) primers at 50°C for 30 min. PCR was performed using Program Temp Control System PC-320 (ASTEC, Fukuoka, Japan). The PCR involved 35 cycles that consisted of denaturation at 94°C for 10 s, annealing at 58°C for 30 s, and extension at 68°C for 30 s. GAPDH was used as an internal control. For a nested RT-PCR amplification of tryptophan hydroxylase (TPH)1, a 5 l of the RT-PCR product using Tph1 outer primers was used as the new template for the second round of amplification using the inner primers (Tph1 inner) and the same amplification condition. The sequence of the oligonucleotide primers used in this study, their positions on the corresponding mRNA sequences, and the expected sizes of the PCR products are shown in Table 1 .
Immunofluorescent staining. After deep anesthesia, C57BL/6 mice (10 wk old) were perfused transcardically with 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M PB (pH7.4), and the urinary bladders, brains, and skeletal muscles (quadriceps femoris) were then isolated. The removed organs were postfixed in the same fixative at 4°C overnight, transferred to 30% sucrose in 0.1 M PB for cryoprotection at 4°C, and then frozen with dry ice. The organs were sectioned at 30 m, floated in 0.01 M PBS, and then stored 4°C until use.
Free-floating sections were rinsed in 0.01 M PBS and treated with blocking solution (0.3% Triton-X and 3% BSA in 0.01 M PBS) to increase the permeability of the antibody and inhibit nonspecific staining at room temperature for 1 h. Next, sections were incubated with goat anti-5-HT 1D polyclonal antibody SR-1D (L-18) or SR-1D (S-18) (1:50, catalog nos. sc-5394 or sc-5393, respectively, Santa Cruz Biotechnology) or goat anti-5-HT 4 polyclonal antibody SR-4 (C-18) or SR-4 (N-18) (1:50, catalog nos. sc-32566 or sc-32564, respectively, Santa Cruz Biotechnology) in blocking buffer at 4°C overnight. Sections were then washed three times in 0.01 M PBS and subjected to a 1 h-incubation with Alexa 488 donkey anti-goat polyclonal antibody (1:500, Molecular Probe) in 0.01 M PBS at room temperature for 1 h. After being washed in 0.01 M PBS, sections were mounted on slides using PermaFluor (Thermo Scientific, Waltham, MA) and visualized by confocal microscopy (Olympus BX61, type FV1000D, Olympus). An absorption test was performed using 2 g antibodies incubated with 80 g of each immunogen blocking peptide (sc-5394 P, sc-5393 P, sc-32566 P, or sc-32564 P, Santa Cruz Biotechnology) instead of the primary antibodies.
ATP release assay using the ussing chamber. A urothelial ATP release assay was performed as previously described (32, 33) . In brief, isolated urinary bladders were opened vertically from the urethra to the apex. The opened bladder was mounted to act as a diaphragm of 7 mm 2 between the two halves of a customized small Ussing chamber. The mucosal (urinary) side of the chamber had a volume of 700 l. Chambers were filled with Krebs solution (117 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl 2, 1.2 mM MgCl2, 24.8 mM NaHCO3, 1.2 mM NaH2PO4, and 11.1 mM glucose) with bubbling 95% O2-5% CO2. In the chemical stimulation assay, serotonin hydrochloride (Sigma) or vehicle (H 2O) was added to the mucosal side for 30 min without hydrostatic pressure. Fifty microliters of Krebs solution were sampled from the mucosal side before and after the addition. ATP release was assessed by subtracting the ATP content before the addition from that after the addition.
In the distention stimulation assay, we applied hydrostatic pressure of 5 cmH 2O to the serosal (smooth muscle) side for 60 min, which reflects the physiological range of pressure during urine storage (49, 52) . Fifty microliters of Krebs solution were sampled from the mucosal side before and 5, 20, 40, and 60 min after application of pressure. Drugs modulating serotonergic signaling were added to the mucosal side 30 min before the application of pressure. The concentrations of drugs used in this study were determined according to previous studies (1, 19, 21, 31) . The ATP content in 50 l Krebs solution on the mucosal side of the chamber was assayed with the luciferin-luciferase method (Kikkoman, Tokyo, Japan) according to the manufacturer's protocol. Standard curves were constructed in each experiment using 3 ϫ 10 Ϫ7 , 3 ϫ 10 Ϫ8 , 3 ϫ 10 Ϫ9 , and 3 ϫ 10 Ϫ10 M ATP. Distention-elicited changes in ATP content were calculated by subtracting the value before pressure was initiated. Since the changes in ATP content at later time points tend to be overestimated because of the gradual reduction in the total volume of Krebs solution, we compared the changes in ATP content under different conditions only at the same time point. Statistically significant differences were detected using an unpaired t-test. All data are expressed as means Ϯ SE.
RESULTS

Expression of 5-HT receptor subtypes in the urothelium.
We performed RT-PCR with total RNA from the urothelium, urothelium-denuded bladder, and brain and investigated the mRNA expression profile of 5-HT receptor subtypes. As shown in Fig. 1 , the urothelium exhibited a distinct mRNA expression pattern compared with the urothelium-denuded bladder. Intense bands corresponding to 5-HT 1D and 5-HT 4 receptors were detected in the urothelium (Fig. 1, top) . Faint bands corresponding to 5-HT 2A and 5-HT 6 receptors was also detected. On the other hand, the urothelium-denuded bladder showed the expression of broader set of 5-HT receptor subtypes: 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 3A , 5-HT 4 , and 5-HT 7 ( Fig. 1, middle) . mRNA expression of all subtypes except for the peripheral subtype 5-HT 2B was detected in the brain, which served as a positive control tissue (Fig. 1, bottom) . A positive 5-HT 2B PCR product was amplified from colorectal tissue (data not shown). These data show that all primer pairs worked well to amplify the 5-HT receptor subtypes in the present study. Fig. 2A) were significantly reduced in the absorption test using blocking immunogen peptide (Fig. 2B) , confirming the specificity of the antibody. Plasma membrane-associated immunoreactivity for 5-HT 1D was observed in the urothelium (Fig. 2C) and detrusor (Fig. 2D) . The arcuate nucleus of the hypothalamus in the brain (positive control tissue) also exhibited neuronal cell membrane-associated immunofluorescent signals (Fig. 2E) , whereas faint fluorescence was found in skeletal muscle (quadriceps femoris, negative control tissue; Fig. 2F ). Immunofluorescent staining using another anti-5-HT 1D antibody, SR-1D (S-18), showed similar results (data not shown).
The bladder wall was also intensely immunostained against the anti-5-HT 4 antibody [SR-4 (C-18); Fig. 3A ]. Immunofluorescent signals were observed on urothelial cells (Fig. 3C , urothelium) in a similar membrane-associated manner. The significant immunoreactivity for 5-HT 4 was also observed in the detrusor (Fig. 3D) . The neuronal cell membrane-associated immunoreactivity in the arcuate nucleus of the hypothalamus (Fig. 3E ) and the subtle fluorescence in the absorption test (Fig.  3B ) and in the musclus quadriceps femoris (Fig. 3F) confirmed the specificity of the antibody. Similar results were obtained by immunofluorescent staining using another anti-5-HT 4 antibody [SR-4 (N-18); data not shown].
Exogenous 5-HT inhibits distention-induced urothelial ATP release via 5-HT 1D . As expression of 5-HT 1D and 5-HT 4 receptors was confirmed in the urothelium, we investigated the effect of exogenously applied 5-HT on urothelial ATP release. RT-PCR analysis of the indicated 5-HT receptor subtypes using total RNA isolated from the mouse urothelium (top), urothelium-denuded bladder (middle), and brain (bottom) is shown. 5-HT1D and 5-HT4 mRNAs were significantly expressed in the urothelium. As a positive control, RT-PCR of GAPDH was performed. The positions of marker bands (100-bp ladder) are indicated to the right of the gels. The expected sizes of PCR products are shown in Table 1 .
The application of 5-HT (10 M) without distention tended to reduce constitutive ATP release (Ϫ0.04 Ϯ 0.03 nM), but the difference from vehicle (H 2 O; 0.01 Ϯ 0.01 nM) was not statistically significant (P ϭ 0.23; Fig. 4A ). On the other hand, exogenous 5-HT produced a significant inhibitory effect on distention-induced ATP release by physiological pressure during urine storage (5 cmH To examine whether the urothelium is the target for 5-HT effects or not, we investigated the effect of exogenous 5-HT on distention-induced ATP release from urothelium-denuded bladder walls. The 5 cmH 2 O-induced ATP release from the urothelium-denuded bladder (0.043 Ϯ 0.012 nM at 20 min, n ϭ 8) was less than that from intact bladder walls, indicating that the most of ATP was released from the urothelium. Exogenous 5-HT (10 M) did not affect distention-induced ATP release from urothelium-denuded bladder walls (0.063 Ϯ 0.028 nM at 20 min, n ϭ 8, P ϭ 0.82 vs.
5-HT by an unpaired t-test).
TPH1 mRNA expression in the urinary bladder and the effect of L-tryptophan or selective serotonin reuptake inhibitor on distention-induced ATP release. The endogenous synthesis, release, and reuptake of 5-HT in the urinary bladder were examined next. First, the expression of mRNAs for TPH1 and TPH2 was investigated by a single or nested RT-PCR methods. A single RT-PCR using Tph1 inner primers or Tph2 primers revealed TPH1 mRNA expression in the small intestine and TPH2 mRNA expression in the brain (Fig. 5A) . On the other hand, neither TPH1 nor TPH2 transcripts were detected in the urinary bladder (Fig. 5A) . Similarly, single RT-PCR using Tph1 outer primers generated no visible band for TPH1 transcripts in the urinary bladder (data not shown). However, a significant level of TPH1 mRNA was detected by nested RT-PCR amplification using Tph1 inner and outer primers (Fig. 5A) .
We then investigated the effect of L-tryptophan, a 5-HT precursor, on distention-induced ATP release (Fig. 5B) . Similar to 5-HT, 1 mM L-tryptophan significantly reduced distention-induced ATP release (0.16 Ϯ 0.06 nM) compared with the vehicle, hydrochloric acid (final concentration: 1 mM, 0.42 Ϯ 0.10 nM, P Ͻ 0.05 by an unpaired t-test). Because hydrochloric acid may activate transient receptor potential vanilloid (TRPV)1 channels and then induce ATP release, we assessed the effects of hydrochloric acid and L-tryptophan on ATP release in the absence of pressure. Hydrochloric acid (1 mM) induced ATP release in the absence of pressure (0.14 Ϯ 0.08 nM), but L-tryptophan did not alter hydrochloric acid-evoked ATP release (0.12 Ϯ 0.05 nM). These results suggest that facilitation of 5-HT synthesis inhibited ATP release due to physiological pressure but not hydrochloric acid.
Next, we evaluated the effect of citalopram, a selective serotonin reuptake inhibitor (SSRI), on distention-induced ATP release. As shown in Fig. 5C , the addition of citalopram (10 M) significantly decreased ATP release (0.09 Ϯ 0.04 nM) to ϳ39% of the vehicle control (0.23 Ϯ 0.03 nM, P Ͻ 0.05 by an unpaired t-test). The extent of inhibition was quite similar to that by exogenous 5-HT (Fig. 4B) , suggesting that 5-HT was endogenously released in the urinary bladder at sufficient levels to fully activate 5-HT receptors in the urothelium.
Distinct functions of 5-HT 1D and 5-HT 4 in distention-induced urothelial ATP release. Because G i/o -coupled 5-HT 1D
and G s -coupled 5-HT 4 receptors have opposite effects on the activities of adenylyl cyclases, the functions of these receptors in distention-induced urothelial ATP release may be different. To elucidate the possible distinct functions of these receptors, we assessed the effect of addition of GR-127935 or SB-204070 without 5-HT. These antagonists exhibited opposite effects on distention-induced ATP release at different times. Twenty minutes after distention (Fig. 6A) 
DISCUSSION
In the present study, we demonstrated the specific expression of 5-HT receptor subtypes in the urothelium and their functional role in distention-induced urothelial ATP release. Expression of mRNAs encoding 5-HT 1D , 5-HT 2A , 5-HT 4 , and 5-HT 6 receptors was detected in the mouse urothelium (Fig. 1) . In addition, plasma membrane-associated localization of 5-HT 1D and 5-HT 4 was shown by the immunofluorescent staining using specific antibodies (Figs. 2 and 3) .
The peripheral 5-HT 1D expression may be characteristic of the urothelium. To our knowledge, the expression and function of 5-HT 1D have not been reported in the urinary bladder, gastrointestinal tract, or other hollow organs, except for vaso- constriction of mucosal vessels (18) . In the urothelium, 5-HT 1D was the dominant 5-HT receptor mediating the inhibitory effect on distention-induced ATP release. ATP release from the urothelium transmits visceral sensations such as bladder wall distention or bladder pain (12, 58) . Therefore, activation of 5-HT 1D may inhibit visceral sensation and extend the urine storage period. Intriguingly, the involvement of 5-HT 1D in the functions of the micturition reflex in the central nervous system has not been reported, whereas the essential contribution of spinal or supraspinal 5-HT 1A to the micturition reflex has been well investigated (8 -10, 26, 56) . These data suggest that 5-HT 1D is quite specific to the peripheral visceral sensation of the urinary bladder, indicating that 5-HT 1D may be a novel target for drug therapy for disorders involving hypersensitivity of the lower urinary tract such as overactive bladder and interstitial cystitis.
5-HT 1D is a G i/o -coupled receptor, and its activation results in inhibition of adenylyl cyclase and a reduction in cAMP. We have previously demonstrated that activation of adenylyl cyclase and an increase in cAMP facilitate urothelial ATP release (34). Therefore, the inhibitory effect of 5-HT 1D on urothelial ATP release may be mediated by a decrease in cAMP.
Expression of 5-HT 4 receptors has been detected in the epithelium of other hollow organs. 5-HT 4 is present in the mucosa of the esophagus, stomach, and intestine (23, 43, 60) , epithelium of the airway (40) , and ovarian epithelium (22) . Activation of 5-HT 4 in the peripheral colorectum results in the inhibition of visceral hypersensitivity (20, 23) . Gastric distention-evoked visceral pain is also inhibited by a 5-HT 4 agonist (50) . These data indicate that 5-HT 4 may be an epithelial-type 5-HT receptor that is involved in visceral sensation. Of note, an increase in distention-induced ATP release from the urothe- lium by 5-HT 4 activation (Fig. 6 ) may lead to enhanced visceral sensation, which is opposite of what occurs in the gastrointestinal tract. In addition to the urothelium, 5-HT 4 is expressed in autonomic nerve terminals in the urinary bladder and facilitates neurogenic contraction of the detrusor (7, 38, 57) . These data suggest that peripheral 5-HT 4 facilitates voiding by enhancing both visceromotor and viscerosensory functions of the urinary bladder. Therefore, the combination of 5-HT 1D activation and 5-HT 4 inhibition may exert a further significant therapeutic effect on lower urinary tract symptoms, as shown in Fig. 6C . Interestingly, the time windows for the effects of endogenous 5-HT 1D and 5-HT 4 were different (5-HT 1D functioned at a later stage and 5-HT 4 functioned at an earlier stage; Fig. 6, A and B) , which implies that 5-HT is a switching molecule from the initial perception of the need to urinate to prolongation of urine storage.
5-HT 2A mRNA expression is also found in native human urothelium but not in human urothelium-derived cell lines (42) . However, the function of 5-HT 2A seems to not be essential in the urothelium, as suggested by its weak expression and the present result showing that the functionally dominant 5-HT receptor subtype was 5-HT 1D .
Our data on 5-HT receptor expression are partially inconsistent with another previous study. Chetty and colleagues (11) reported 5-HT 3A and 5-HT 3B mRNA expression in the mouse bladder mucosa, whereas we detected 5-HT 3A expression only in the urothelium-denuded urinary bladder. Although such a discrepancy may be due to the different positions of the primer pairs, the primer pairs for 5-HT 3A in the present study amplified mouse 5-HT 3A mRNA in the brain (Fig. 1) and the mucosa-denuded colorectum (data not shown). An alternative explanation is that the different methods by which the urothelium was removed may have caused the discrepancy. If the bladder mucosa in the study by Chetty and colleagues included the lamina propria, the discrepancy could be accounted for by the 5-HT 3A expression in the lamina propria, because the lamina propria was left in the urothelium-denuded bladder in the present study.
We have shown a small but significant amount of TPH1 mRNA expression in the urinary bladder by nested RT-PCR (Fig. 5A) , suggesting that 5-HT could be endogenously synthesized. The present result using L-tryptophan or an SSRI (Fig. 5, B and C) also imply the endogenous synthesis and release in the isolated urinary bladder. Although the cell type that synthesizes and releases 5-HT remains unknown, several studies have implied that mast cells may be a source of 5-HT in the urinary bladder. TPH is expressed in mast cells in human and normal rat gastrointestinal tracts (61) , and mast cells synthesize 5-HT from 5-hydroxytryptophan (59) . Mast cells are predominantly located around submucosal and adventitial blood vessels with infiltration of the lamina propria and muscularis propria in the urinary bladder of normal female rats (30) . Although further studies are necessary to identify the source of 5-HT in the urinary bladder, the significant effect of 5-HT 1D or 5-HT 4 antagonist alone on distention-induced ATP release (Fig. 6, A and B) indicates that the amount of endogenously-released 5-HT is sufficient to exert its functions through these receptors.
In summary, we identified specific expression of 5-HT 1D and 5-HT 4 receptors in the urothelium and their functions in distention-evoked ATP release from the urothelium. 5-HT 1D was the functionally dominant receptor mediating serotonergic inhibition of urothelial ATP release, which leads to inhibition of visceral sensation, whereas 5-HT 4 facilitated urothelial ATP release. 5-HT 1D is likely to be a urothelium-specific receptor subtype in the system that regulates micturition. Since urothelial ATP release was significantly elevated in interstitial cystitis (54) and was correlated with urinary frequency in overactive bladder patients (53) , activation of 5-HT 1D may be a novel specific therapy for the treatment of disorders involving frequent urination or bladder pain.
